Publications
Detailed Information
Effectiveness and tolerability of long-acting risperidone: A 9-month open-label extension of a 12-week switching study from oral antipsychotics
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Chang Yoon | - |
dc.contributor.author | Chung, Seockhoon | - |
dc.contributor.author | Hahm, Bong-Jin | - |
dc.contributor.author | Hong, Kyung Sue | - |
dc.contributor.author | Kim, Young-Hoon | - |
dc.contributor.author | Lee, Sang-Yeol | - |
dc.contributor.author | Chung, In-Won | - |
dc.contributor.author | Kim, Chan-Hyung | - |
dc.contributor.author | Lee, Yanghyun | - |
dc.contributor.author | Bahk, Won-Myong | - |
dc.contributor.author | Yoon, Jin-Sang | - |
dc.date.accessioned | 2012-07-04T08:59:26Z | - |
dc.date.available | 2012-07-04T08:59:26Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE; Vol.13(3); 192-198 | ko_KR |
dc.identifier.issn | 1365-1501 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78495 | - |
dc.description.abstract | Objectives. The aim of this non-randomized, single-arm, multi-center, 9-month extension study was to evaluate the maintained efficacy and tolerability of long-acting risperidone injection when we switched to it from previous oral antipsychotics in symptomatically stable patients with schizophrenia or other psychotic disorders. Methods. A total of 98 patients who had completed a previous 12-week acute phase study were included. Efficacy and tolerability were assessed with the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI), Global Assessment of Functioning (GAF), and Extrapyramidal Symptom Rating Scale (ESRS). Results. The remission rate of 77.6% (76/98) at baseline and 57.1% (56/98) at the end of the study. Of patients who were in remission at baseline, 65.8% (50/76) maintained their remission state until the end. The symptom worsening rate was relatively low (11.1%), and there was no aggravation in mean PANSS total and subscale scores. Spontaneous treatment-emergent adverse events (TEAE) were reported by 21 (21.4%) patients, and most commonly reported adverse events were extrapyramidal symptoms (N=6, 6.1%) and insomnia (N=4, 4.1%). Extrapyramidal symptoms were significantly improved. Conclusions. Switching to long-acting risperidone injection from oral antipsychotics was a safe and well-tolerated strategy for maintaining clinical stability in symptomatically stable patients with schizophrenia. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | Informa Healthcare | ko_KR |
dc.subject | Long-acting injection | ko_KR |
dc.subject | risperidone | ko_KR |
dc.subject | maintenance | ko_KR |
dc.subject | remission | ko_KR |
dc.title | Effectiveness and tolerability of long-acting risperidone: A 9-month open-label extension of a 12-week switching study from oral antipsychotics | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김창윤 | - |
dc.contributor.AlternativeAuthor | 정석훈 | - |
dc.contributor.AlternativeAuthor | 함봉진 | - |
dc.contributor.AlternativeAuthor | 홍경수 | - |
dc.contributor.AlternativeAuthor | 윤진상 | - |
dc.contributor.AlternativeAuthor | 김영훈 | - |
dc.contributor.AlternativeAuthor | 박원명 | - |
dc.contributor.AlternativeAuthor | 이상열 | - |
dc.contributor.AlternativeAuthor | 이양현 | - |
dc.contributor.AlternativeAuthor | 정인원 | - |
dc.contributor.AlternativeAuthor | 김찬형 | - |
dc.identifier.doi | 10.1080/13651500902737000 | - |
dc.citation.journaltitle | INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE | - |
dc.description.citedreference | van Os J, 2006, ACTA PSYCHIAT SCAND, V113, P91, DOI 10.1111/j.1600-0447.2005.00659.x | - |
dc.description.citedreference | Sethuraman G, 2005, SCHIZOPHR RES, V79, P337, DOI 10.1016/j.schres.2005.06.015 | - |
dc.description.citedreference | Lasser RA, 2005, SCHIZOPHR RES, V77, P215, DOI 10.1016/j.schres.2005.03.006 | - |
dc.description.citedreference | Gastpar M, 2005, J PSYCHOPHARMACOL, V19, P32, DOI 10.1177/0269881105056598 | - |
dc.description.citedreference | Parellada E, 2005, J PSYCHOPHARMACOL, V19, P5, DOI 10.1177/0269881105056513 | - |
dc.description.citedreference | Chouinard G, 2005, SCHIZOPHR RES, V76, P247, DOI 10.1016/j.schres.2005.02.013 | - |
dc.description.citedreference | Andreasen NC, 2005, AM J PSYCHIAT, V162, P441 | - |
dc.description.citedreference | CHUNG S, 2005, KOREAN J PSYCHOPHARM, V16, P109 | - |
dc.description.citedreference | Lindenmayer JP, 2004, J CLIN PSYCHIAT, V65, P1084 | - |
dc.description.citedreference | van Os J, 2004, INT CLIN PSYCHOPHARM, V19, P229, DOI 10.1097/01.yic.0000122861.35081.16 | - |
dc.description.citedreference | Correll CU, 2004, AM J PSYCHIAT, V161, P414 | - |
dc.description.citedreference | Lehman AF, 2004, AM J PSYCHIAT, V161, P1 | - |
dc.description.citedreference | Harrison TS, 2004, CNS DRUGS, V18, P113 | - |
dc.description.citedreference | Beasley CM, 2003, J CLIN PSYCHOPHARM, V23, P582, DOI 10.1097/01.jcp.0000095348.32154.ec | - |
dc.description.citedreference | Fleischhacker WW, 2003, J CLIN PSYCHIAT, V64, P1250 | - |
dc.description.citedreference | Lieberman JA, 2003, NEUROPSYCHOPHARMACOL, V28, P995, DOI 10.1038/sj.npp.1300157 | - |
dc.description.citedreference | Kane JM, 2003, J CLIN PSYCHIAT, V64, P19 | - |
dc.description.citedreference | Kane JM, 2003, J CLIN PSYCHIAT, V64, P34 | - |
dc.description.citedreference | Robinson DG, 2002, SCHIZOPHR RES, V57, P209 | - |
dc.description.citedreference | Csernansky JG, 2002, NEW ENGL J MED, V346, P16 | - |
dc.description.citedreference | Dolder CR, 2002, AM J PSYCHIAT, V159, P103 | - |
dc.description.citedreference | Gitlin M, 2001, AM J PSYCHIAT, V158, P1835 | - |
dc.description.citedreference | KANE G, 1999, YEARB LANGL, V13, P7 | - |
dc.description.citedreference | Kane JM, 1998, EUR NEUROPSYCHOPHARM, V8, P55 | - |
dc.description.citedreference | DAVIS JM, 1994, DRUGS, V47, P741 | - |
dc.description.citedreference | HOGAN TP, 1992, PSYCHOL MED, V22, P347 | - |
dc.description.citedreference | WARE JE, 1988, MED CARE, V26, P393 | - |
dc.description.citedreference | ERESHEFSKY L, 1984, J CLIN PSYCHIAT, V45, P50 | - |
dc.description.citedreference | DAVIS JM, 1975, AM J PSYCHIAT, V132, P1237 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.